Sign inCreate account

Report workspace tools

NCT03869762TERMINATEDanonymous

A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

Sponsor

Source record

Cancer Trials Ireland

Phase

Source record

Phase II

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Castration-resistant Prostate Cancer

Indication / condition

AI-normalized

Castration-resistant Prostate Cancer

Intervention

Source record

Xgeva, Xtandi

Source & freshness

Source record

NCT ID

NCT03869762

Original source

ClinicalTrials.gov

Source last updated

Apr 13, 2026

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03869762

Title

A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

Sponsor

Cancer Trials Ireland

Status

TERMINATED

Phase

Phase II

Condition raw

Castration-resistant Prostate Cancer

Condition normalized

Castration-resistant Prostate Cancer

Modality raw

Castration-resistant Prostate Cancer

Modality normalized

monoclonal antibody

Target raw

Castration-resistant Prostate Cancer

Target normalized

Castration-resistant Prostate Cancer

Interventions

Xgeva, Xtandi

Public preview

Source record

The DICE trial investigated the combination of Denosumab and Enzalutamide in patients with progressive metastatic castration-resistant prostate cancer and bone metastases. The study was terminated due to insufficient patient accrual, with only 7 participants enrolled.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase II Study of Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03869762

Status

TERMINATED

Phase

Phase II

Sponsor

Cancer Trials Ireland

Executive brief

Investment-Ready Snapshot

The DICE trial investigated the combination of Denosumab and Enzalutamide in patients with progressive metastatic castration-resistant prostate cancer and bone metastases. The study was terminated due to insufficient patient accrual, with only 7 participants enrolled.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 13, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03869762

Indication

Castration-resistant Prostate Cancer

Modality

monoclonal antibody

Target

Castration-resistant Prostate Cancer

Intervention

Xgeva, Xtandi

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.